Literature DB >> 11018691

Erythrocyte protoporphyrins in hepatitis C viral infection.

M Vogeser1, K Jacob, R Zachoval.   

Abstract

OBJECTIVES: Protoporphyrin is the immediate precursor of the heme molecule. Due to a spillover from hemaotopoietic tissue it is regularly found in small amounts in erythrocytes and excreted into the bile. In hereditary erythropoietic protoporphyria excess protoporphyrin accumulates and can cause severe liver damage both by crystallization and induction of oxidative stress. The aim of this investigation was to study protoporphyrin concentrations in other liver disorders. DESIGN AND METHODS: Erythrocyte protoporphyrin and zinc protoporphyrin concentrations were studied in 50 patients with chronic hepatitis C infection and various degrees of liver damage. High-performance liquid chromatographic analysis with fluorescence detection was used.
RESULTS: Erythrocyte protoporphyrin was increased in 32% of the patients studied; in 12 patients up to two-fold higher than the maximum of the reference range, in 4 up to three-fold higher (median concentration 98 nmol/L, interquartile range 68-142; maximum 379 nmol/L (reference range: <125 nmol/L)). In 6 of the 10 patients in the subgroup with signs of severe liver dysfunction (decreased serum albumin and prolonged thromboplastin time, elevated serum bilirubin), protoporphyrin was elevated. Erythrocyte zinc protoporphyrin was increased in 7 cases out of all 50 studied; in these seven cases, erythrocyte protoporphyrin was also elevated (median concentration of zinc protoporphyrin in the whole study group: 232 nmol/L, interquartile range 182-342; maximum 827 nmol/L (reference range <464 nmol/L).
CONCLUSIONS: Elevated erythrocyte protoporphrin levels are frequently found in patients with advanced chronic hepatitis C infection. Because protoporphyrin is well known to be hepatotoxic, these findings warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018691     DOI: 10.1016/s0009-9120(00)00149-1

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Erythrocyte protoporphyrin fluorescence as a biomarker for monitoring antiangiogenic cancer therapy.

Authors:  Flávia Gomes de Góes Rocha; Karen Cristina Barbosa Chaves; Cinthia Zanini Gomes; Camila Barricheli Campanharo; Lilia Coronato Courrol; Nestor Schor; Maria Helena Bellini
Journal:  J Fluoresc       Date:  2010-05-18       Impact factor: 2.217

2.  Erythrocyte Protoporphyrin Fluorescence as a Biomarker to Monitor the Anticancer Effect of Semecarpus Anacardium in DMBA Induced Mammary Carcinoma Rat Model.

Authors:  Haseena Banu Hedayathullah Khan; S Vani; Shanthi Palanivelu; Sachdanandam Panchanadham
Journal:  J Fluoresc       Date:  2015-05-06       Impact factor: 2.217

3.  Changing trends in the epidemiology of pediatric lead exposure: interrelationship of blood lead and ZPP concentrations and a comparison to the US population.

Authors:  Offie Porat Soldin; John C Pezzullo; Brian Hanak; Maureen Miller; Steven J Soldin
Journal:  Ther Drug Monit       Date:  2003-08       Impact factor: 3.681

4.  Pediatric reference ranges for zinc protoporphyrin.

Authors:  Offie Porat Soldin; Maureen Miller; Steven J Soldin
Journal:  Clin Biochem       Date:  2003-02       Impact factor: 3.281

5.  The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany.

Authors:  M O Doss; T Stauch; U Gross; M Renz; R Akagi; M Doss-Frank; H P Seelig; S Sassa
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

6.  Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: a cluster-randomized trial.

Authors:  Souheila Abbeddou; Elizabeth Yakes Jimenez; Jérome W Somé; Jean Bosco Ouédraogo; Kenneth H Brown; Sonja Y Hess
Journal:  BMC Pediatr       Date:  2017-02-02       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.